$NL

P/E Ratio Insights for NL Industries - NL Industries (NYSE:NL)

In the current session, NL Industries Inc. NL is trading at $6.12, after a 2.00% decrease. Over the past month, the stock fell by 4.30%, and in the past year, by 6.36%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio.

Original reporting
Benzinga · Benzinga Insights
Published Aug 19, 2025, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$NL
Neutral
medium confidence
Mentioned
$NL
Relevance
6/10
AlphAI data visualization · based on Benzinga
Decision brief

The 30-second read

$NLNeutralMed
01

Why it matters

Given the lack of a concrete P/E figure, the immediate impact is likely muted pending earnings or guidance catalysts. Traders may price in valuation considerations, but absent a clear metric, volatility will depend on broader market sentiment and sector movements.

02

Market read

Moderate relevance for traders tracking Life Sciences and small-cap valuation narratives; NL’s valuation discussion is unlikely to drive broad market moves but could influence sentiment around peers.

03

What to watch

Catalysts such as earnings surprises, regulatory developments, product approvals, or sector-wide multiple expansion/contraction could override the sentiment implied by the current P/E discussion. Liquidity and macro conditions may also play a significant role.

Relevance 6/10Timing: near-term

Background

Benzinga's insights piece analyzes NL Industries’ price/earnings ratio as a valuation lens. NL currently trades around $6.12 after a 2% intraday decline; over the last month the stock is down 4.3% and down 6.36% year over year. The article emphasizes valuation interpretation but does not provide an explicit P/E value.

Company-level read

Ticker impact

$NLNeutralMedium confidence
Context

Limited explicit P/E data; current price around $6.12 after a 2% intraday decline; monthly and annual declines suggest cautious valuation sentiment.

Expected impact

Near-term consolidation with modest downside bias; expected trading range roughly 5.95 to 6.40 over the next 1-4 weeks. Probability: ~25% of breaking above 6.40, ~25% of breaking below 5.95, ~50% staying within 5.95-6.40.

Evidence & confidence

No explicit P/E value provided in the article; price has recently declined, suggesting cautious sentiment. Without concrete catalysts, movement will likely hinge on generic valuation narratives and broader market tone.

Market effects

Valuation-centric narratives in Life Sciences and related sectors may lead to broader re-rating pressures; cautious tone on mid-cap valuations could influence sentiment across peers.

Limited; NL is a US-listed mid-cap in a niche sector; broad regional impact unlikely.

Low; company-specific valuation discussion with minimal global macro relevance.

Counterpoint

The absence of a reported P/E value could mean the market expects earnings volatility or valuation uncertainty; however, if the company reports favorable earnings or guidance, the stock could re-rate despite the current narrative.

Key entities

  • NL Industries

    NYSE:NL; Life Sciences-focused company; subject of P/E ratio valuation discussion in the Benzinga article.

Related articles

$NLMed

NLI REPORTS SECOND QUARTER 2026 RESULTS

NLI HOLDINGS, INC. (NL) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ ​ ​ ​ ​ ​ ​ ​ NLI REPORTS SECOND QUARTER 2026 RESULTS ​ DALLAS, TEXAS – August 5, 2026 – NLI Holdings, Inc. (NYSE: NL) reported net income attributable to NLI stockholders of $9.0 million, or $.18 per share, in the second quarter of 2026 compared to $.3 million, or $.01 per sha

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$BHPHigh

BHP awards $200M contract for Ministers North Project

BHP awarded a $200M contract to Q H & M Birt for a 13km haul road at its $1.3B Ministers North Project, targeting 20Mt/year iron ore output by 2029. BHP's share price was $57.56 post-announcement. Earlier, GR Engineering received a $230M contract for the project.